Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
The invention, describes an efficient platform for antibody manufacturing and formulation, that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L； ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels； and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include lgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and lgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.
